T.N. Pierce | AMiner学者主页

全面呈现 [T.N. Pierce] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

论文（2）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1250Program Overview: Diseases Treated, Types of Transplants, Regimens and Outcome in an Outpatient Blood and Marrow Transplant Program

Wilson M.C.,King J.,Scott L.M.,Pierce T.N.,Shamlou R.,Saracino G.,White M.,Agura E.D.,Berryman R.B.,Fay J.W.,Pineiro L.,Vance E.A.

2003Biology of Blood and Marrow Transplantation（2003）

引用

AI阅读

2201CD34+ Counts after Etoposide and Cyclophosphamide Plus G-CSF Mobilization Versus G-CSF Alone in Multiple Myeloma Patients Undergoing Autologous Transplantation

Pierce T.N.,Scott L.M.,White M.,Agura E.,Berryman R.B.,Fay J.W.,Vance E.,Pineiro L.

Poster Presentations -Session II transplantation (SCT) for lymphomas and the engraftment of donor immnnocompetent cells is essential.The height of host "immunological barrier" belongs to the major factors influencing engraftment.Some patients transplanted after non myeloablative regimens finally reconstituted their own immunocompetent cells because of insufficient immunosuppression and there has been no room for GvL effect.On the other hand, many pretrcated immunocompromised recipients developed severe complications due to unnecessary toxicity.11 patients with non-hodgkin lym pbomas (NHL -8x) and chronic lymphatic leukemia (CLL -3x) underwent non-myeloablative allogeneie SCT fronl sibling donor.No one of them was in complete remision (CR) before SCT.The recipients with the pretransplant level of CD3+ cells below than 0, 5x10 9/L were grafted after conditioning combined flndarabin (125rag/m2) and cyclophosphamide (120mg/kg).Those ones with CD3+ cells above 0, 5x10 9/L underwent SCT after fludarabin and melphalan (140rag/m2), fludarabin, melphalan and ATG (40mg/kg)or fludarabin, cyclophosphamide and ATG.The "graft versus host disease" (GvHD) prophyla~s consisted of cyclosporine A (CsA) only or CsA combined with the short-course of methotrexate (MTX).Donor chilnerism was evaluated in T-cell population at day +30, +60, +100 after SCT.CsA tapering depended on the grade of donor chimerism in T-cells. 10 patients (90, 0%) achieved complete donor chimerism in T-cells and sustained CR of their disease at the posttransplant follow-up period (median 134 days).6 recipient (54, 5%) developed GvHD.3 patients (27, 3%) died of transplant-related complications.The combination of fludarabin and cyclophosphamide (+/-ATG) was associated with significantly lower to, city and allowed sufficient engraftment of donor cells with effective immunological mmour control in severe immunocompromised hosts.The reduction of conditioningorelated to,city without the decrease of CR rate fully advocate the pretransplant evaluation of T-cell populations in recipients.

2003Biology of Blood and Marrow Transplantation（2003）

引用

AI阅读